Sign in
Active, not recruitingPhase 2

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

Key facts

Who runs it
Institute of Hematology & Blood Diseases Hospital, China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
48 people enrolled
Started
24 Oct 2024
Expected to end
30 Sept 2027
Type of study
Interventional
Treatments tested
  • standard IST combined with Romiplostim N01
Record updated
4 November 2026

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥ 12 years
  • Diagnosis of severe or very severe aplastic anemia
  • Patients are unconditionally or unacceptable undergoing allogeneic hematopoietic stem cell transplantation
  • ECOG performance status ≤2
  • Willing and able to comply with the requirements for this study and written informed consent

Who cannot take part

  • Received > 4 weeks of TPO-RA drug before treatment
  • Received > 4 weeks of immunosuppressive therapy before treatment
  • History of thromboembolic disease
  • Allergy to ALG
  • Presence of uncontrolled active infection
  • History of chemoradiotherapy for malignant solid tumors
  • History of other systemic serious illnesses
  • Presence of uncontrolled hypertension (≥140/90mmHg), diabetes mellitus (fasting blood glucose≥ 7.0 mmol/L or random blood glucose ≥ 11.1 mmol/L)
  • Abnormal liver and kidney function: Aspartate Transaminase (AST) or Alanine Transaminase (ALT) > 3 ULN, creatinine ≥ 2.5 ULN
  • Intolerance to Romiplostim N01 or cyclosporine
  • Females who are pregnant/lactating or need pregnancy
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, single center, single-arm study aims to evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (p-ALG) in combination with cyclosporine and Romiplostim in treating severe aplastic anemia (SAA). It will include 48 patients with newly diagnosed SAA.

The group in the trial

  • p-ALG+Romiplostim N01+CsATreatment being tested

    The maximum screening period was 4 weeks, and after entering the treatment period, the patients were treated with p-ALG combined with cyclosporine and Romiplostim N01. Symptomatic leukocyte elevation, blood transfusion support, and anti-infective therapy are allowed during this period, according to the patient's blood routine. If a patient has a serious adverse event during treatment, it will be treated according to the criteria for suspension and recovery.

    Treatment: standard IST combined with Romiplostim N01

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single Center, Single-arm Study on the Efficacy and Safety of Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
Record updated
4 November 2026